Sight Sciences, Inc. (NASDAQ:SGHT) Stock Now Rated "Moderate Buy" by Wall Street Analysts

Key Points

• Analysts rate SGHT “Moderate Buy”: Five of eight covering brokerages recommend buying, two rate it a hold and one a sell. The average 12-month price target is $9.62.
• Quarterly revenue beat estimates: Sight Sciences reported revenue of $24.92 million versus analysts’ $23.55 million forecast, while its $0.12-per-share loss matched expectations. The company remains unprofitable.
• Growth outlook received a boost: Sight Sciences raised its full-year revenue guidance to $92–$93 million and indicated a higher 2026 iDose revenue target. CMS also established a practice-expense supply code for TearCare SmartLids, potentially clarifying reimbursement.

Shares of Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) have been given an average rating of "Moderate Buy" by the eight brokerages that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $9.62.

A number of equities research analysts have issued reports on SGHT shares. Citigroup boosted their target price on shares of Sight Sciences from $8.00 to $10.00 and gave the company a "neutral" rating in a report on Monday, October 5th. Wall Street Zen raised Sight Sciences from a "hold" rating to a "buy" rating in a report on Saturday, August 8th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Sight Sciences in a research report on Friday, August 7th. HC Wainwright initiated coverage on Sight Sciences in a research note on Thursday, October 15th. They set a "buy" rating and a $14.00 price objective on the stock. Finally, Piper Sandler reiterated an "overweight" rating and set a $12.00 price objective (up from $9.00) on shares of Sight Sciences in a research note on Thursday.

Insider Buying and Selling

In other news, CEO Paul Badawi sold 29,653 shares of the stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $9.05, for a total value of $268,359.65. Following the sale, the chief executive officer directly owned 6,092,819 shares of the company's stock, valued at approximately $55,140,011.95. This represents a 0.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CTO David Badawi sold 7,797 shares of the firm's stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $9.05, for a total transaction of $70,562.85. Following the completion of the transaction, the chief technology officer owned 1,975,075 shares of the company's stock, valued at $17,874,428.75. This trade represents a 0.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 47,646 shares of company stock worth $429,157 over the last quarter. 30.40% of the stock is owned by corporate insiders.

Institutional Trading of Sight Sciences

Several institutional investors and hedge funds have recently bought and sold shares of SGHT. BlackRock Inc. purchased a new position in Sight Sciences during the second quarter worth about $16,710,000. GSA Capital Partners LLP bought a new position in Sight Sciences in the 2nd quarter worth about $908,000. Bank of New York Mellon Corp purchased a new stake in shares of Sight Sciences in the 2nd quarter valued at about $495,000. Bank of America Corp DE purchased a new stake in shares of Sight Sciences in the 2nd quarter valued at about $520,000. Finally, SCS Capital Management LLC purchased a new stake in shares of Sight Sciences in the 2nd quarter valued at about $488,000. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Sight Sciences

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: Higher 2026 outlook: Sight Sciences raised its full-year revenue guidance to $92–$93 million and indicated a higher 2026 revenue target for its iDose product. The improved outlook may support expectations for continued growth. Article: Sight Sciences signals 2026 revenue outlook
• Positive Sentiment: CMS reimbursement development: CMS established a direct practice-expense supply code for TearCare SmartLids, a single-use component of the TearCare system. This could help clarify reimbursement and support adoption. Article: CMS establishes a TearCare SmartLids supply code
• Positive Sentiment: Revenue beat and analyst support: Third-quarter revenue was $24.92 million, above analysts’ $23.55 million estimate. Piper Sandler reaffirmed its Overweight rating and raised its price target to $12 from $9, signaling confidence in further upside. Analyst rating information
• Neutral Sentiment: Losses persist, but met expectations: SGHT reported a third-quarter loss of $0.12 per share, in line with consensus and narrower than the $0.16 loss a year earlier. The company remains unprofitable, which may temper the positive growth news. Article: Sight Sciences reports Q3 loss and revenue beat

Sight Sciences Price Performance

SGHT opened at $9.76 on Friday. The company has a market capitalization of $537.68 million, a price-to-earnings ratio of -18.77 and a beta of 2.44. The company has a quick ratio of 4.67, a current ratio of 4.95 and a debt-to-equity ratio of 0.58. The firm has a 50-day moving average price of $8.68 and a 200-day moving average price of $6.07. Sight Sciences has a twelve month low of $3.38 and a twelve month high of $10.31.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($0.12) EPS for the quarter, meeting analysts' consensus estimates of ($0.12). The company had revenue of $24.92 million for the quarter, compared to analysts' expectations of $23.55 million. Sight Sciences had a negative net margin of 32.13% and a negative return on equity of 42.41%. Equities analysts expect that Sight Sciences will post -0.48 EPS for the current year.

About Sight Sciences

Sight Sciences, Inc is an ophthalmic medical technology company focused on developing and commercializing products designed to address the underlying causes of certain eye diseases. The company's portfolio is centered on minimally invasive and non-invasive procedures intended to improve patient outcomes while supporting physicians in the treatment of glaucoma and ocular surface disease.

Its primary products include the OMNI Surgical System, a minimally invasive glaucoma surgery device used to reduce intraocular pressure by improving the eye's natural fluid outflow pathways, and the TearCare System, a thermal pulsation technology designed to treat meibomian gland dysfunction, a common cause of evaporative dry eye disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.